SCHEMBL525920

SCHEMBL525920

ONCCOCCNO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9955330 0.96 MEN1 (0.39)
SCHEMBL559048 0.96 MEN1 (0.39)
SCHEMBL1154318 0.96 MEN1 (0.39)
SCHEMBL20432272 0.87
SCHEMBL12896587 0.86
SCHEMBL18970642 0.85
SCHEMBL9327882 0.85
SCHEMBL24936533 0.83 KDM4E (0.36)
SCHEMBL16328524 0.83 MEN1 (0.31)
SCHEMBL12143358 0.83 MEN1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11564992-B2 Nucleophilic catalysts for oxime linkage TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-31 US claimed
CN-109620963-B Nucleophilic catalysts for oxime linkage 武田药品工业株式会社 2022-10-28 CN claimed
EP-4023247-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE Takeda Pharmaceutical Company Limited (JP) 2022-07-06 EP claimed
EP-4019049-A1 METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES Takeda Pharmaceutical Company Limited (JP) 2022-06-29 EP claimed
EP-3505186-B1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE TAKEDA PHARMACEUTICALS CO (JP) 2022-01-12 EP claimed
US-20210163527-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-03 US claimed
US-20200230252-A1 NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 US claimed
EP-3673921-A1 MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN Baxalta GmbH (CH) 2020-07-01 EP claimed
EP-2654794-B1 MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN Baxalta GmbH (CH) 2020-03-04 EP claimed
US-10576160-B2 Nucleophilic catalysts for oxime linkage BAXALTA INCORPORATED (US) 2020-03-03 US claimed
US-20110027350-A1 GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS LIPOXEN TECHNOLOGIES LIMITED (GB) 2011-02-03 US claimed
US-20100009917-A1 Modulating Enzymatic Processes by Addition of Diolcontaining Substances NOVO NORDISK HEALTH CARE AG (CH) 2010-01-14 US claimed
EP-2121952-A1 MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES Novo Nordisk Health Care AG (CH) 2009-11-25 EP claimed
US-20090264366-A1 Transglutaminase Mediated Conjugation of Peptides NOVO NORDISK HEALTHCARE AG (CH) 2009-10-22 US claimed
EP-2033662-A1 Transglutaminase mediated conjugation of peptides Novo Nordisk Health Care AG (CH) 2009-03-11 EP claimed
WO-2008101957-A1 MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES NOVO NORDISK HEALTH CARE AG (DK) 2008-08-28 WO claimed
JP-2007518747-A 2007-07-12 JP claimed
US-20070105770-A1 Transglutaminase mediated conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-10 US claimed
EP-1708755-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2006-10-11 EP claimed
WO-2005070468-A2 TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES NOVO NORDISK A/S (DK) 2005-08-04 WO claimed